Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

Small molecules in the treatment of COVID-19

Antioxidants, Free Full-Text

Iota-carrageenan inhibits replication of SARS-CoV-2 and the respective variants of concern alpha, beta, gamma and delta

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

Full article: Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease

Pharmaceutics, Free Full-Text

Marine Drugs, Free Full-Text

Inhibitory Effect of Iota-carrageenan on Porcine Reproductive and Respiratory Syndrome Virus in Vitro - Chunhe Guo, Zhenbang Zhu, Piao Yu, Xiaoxiao Zhang, Wenjuan Dong, Xiaoying Wang, Yaosheng Chen, Xiaohong Liu, 2019

BREAKING! Latest German Study Reinforces Past Research Showing Iota- Carrageenan Ability To Inhibit Replication Of All SARS-CoV-2 VOCs. - Thailand Medical News

Carrageenan-based composite nasal spray may help prevent SARS-CoV-2 infection

The antiviral activity of iota-, kappa-, and lambda-carrageenan against COVID-19: A critical review - ScienceDirect

Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2